Wilson Disease: Symptoms, Diagnosis and Treatment — A Hepatologist’s Guide

Wilson disease is an inherited disorder in which a faulty ATP7B gene stops the liver clearing copper, so copper accumulates in the liver, brain and eyes. It is one of the few genuinely treatable causes of cirrhosis in young people — but treatment is lifelong. In Wilsonian acute liver failure, a New Wilson Index score of 11 or above predicts death without liver transplantation.

— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai

A nineteen-year-old engineering student is referred to me because a pre-employment blood test showed an SGPT of 180. He feels perfectly well. He has never touched alcohol. His family is convinced the laboratory erred.

Sometimes it is Wilson disease.

Wilson disease is rare in the way that matters clinically — common enough that every hepatologist in India encounters it, uncommon enough that it is missed for years. Copper the liver ought to excrete into bile accumulates instead: silently at first, then in the brain, then visibly in the eyes. Patients are diagnosed only after cirrhosis has formed, or during an episode of acute liver failure that a blood test five years earlier could have prevented.

What makes it worth chasing hard is that Wilson disease responds to treatment. Among the causes of cirrhosis I manage — alcohol, hepatitis B, fatty liver — few offer a genuine chance to halt and even reverse damage with tablets alone. The catch sits in one word: faithfully.

Why copper accumulates: the ATP7B defect in plain terms

All of us absorb more copper from food than the body needs. A protein called ATP7B, made in liver cells, handles the surplus — loading some onto ceruloplasmin for transport in blood, pushing the rest into bile for excretion. In Wilson disease the ATP7B gene on chromosome 13 carries variants that leave the protein unable to do that work.

Copper then behaves as any unmanaged metal does. It builds up inside hepatocytes, injures them, and eventually spills into the bloodstream, depositing in the basal ganglia of the brain, in Descemet’s membrane at the corneal margin, and in the kidneys. Damage accrues quietly for years before anything declares itself.

Inheritance is autosomal recessive: both parents carry one faulty copy without being ill, and each pregnancy carries a one-in-four chance of an affected child. Marriage within a closely related community raises the odds of two carriers meeting — relevant in parts of India, and reflected in the South Asian data, where roughly a third of children in one regional series of Wilsonian liver failure came from consanguineous unions. Most patients present between late childhood and the fourth decade, though the 2022 AASLD Practice Guidance is explicit that Wilson disease affects patients of all ages. Age alone should never be the reason a clinician sets the diagnosis aside.

How Wilson disease shows up — and why it gets missed

Three faces of one illness present to three different specialists, which is why the diagnosis scatters.

The liver presentation ranges from persistently raised transaminases in an otherwise well young person, through an acute hepatitis indistinguishable at first from a viral illness, to cirrhosis found incidentally on ultrasound. Some arrive decompensated, with jaundice and ascites. A smaller group presents in acute liver failure — dealt with separately below, because it is a genuine emergency with its own diagnostic shortcuts.

The neurological presentation tends to appear later: coarse tremor, dystonia, slurred speech, drooling, an unsteady gait, handwriting that has deteriorated over months. The psychiatric presentation is the cruellest, because it looks like adolescence. Personality change, collapsing academic performance, irritability, depression — families and teachers explain these away for years before anyone checks a liver enzyme.

Kayser-Fleischer rings, the golden-brown copper deposits at the corneal margin, are present in almost every patient with neurological involvement and frequently absent when disease is confined to the liver. Their absence rules nothing out. They must be looked for by an ophthalmologist on a slit lamp — never by torchlight in a consulting room.

Making the diagnosis: no single test is enough

Wilson disease is diagnosed by assembling evidence, not by one result. A low serum ceruloplasmin supports the diagnosis but cannot establish it, and this is where most delays begin. Ceruloplasmin is an acute-phase reactant — infection, inflammation, pregnancy and oestrogen-containing pills all push it up, so a patient with Wilson disease can return a reassuringly normal value. It also falls in unrelated conditions, including protein-losing states.

Genetic testing has become considerably more accessible in India, and it does two things at once: it settles an ambiguous diagnosis, and it makes screening relatives straightforward. The Leipzig scoring system, used in both the EASL and AASLD guidance, exists to combine these findings into a single diagnostic probability rather than leaving clinicians to weigh them by instinct.

In my practice the commonest reason a diagnosis is delayed by years is depressingly simple. Somebody orders a ceruloplasmin in isolation, it returns borderline, and the workup stops there.

The emergency: Wilsonian acute liver failure

A small number of patients present not with abnormal enzymes but with a liver that is failing over days. Wilsonian acute liver failure is fatal without transplantation, which makes speed of diagnosis the whole game — and here the conventional copper tests let you down badly. In the landmark comparison from the US Acute Liver Failure Study Group, a serum ceruloplasmin below 20 mg/dL measured by the oxidase method identified only 21% of patients who genuinely had the disease. Waiting on ceruloplasmin in this setting costs days that patients do not have.

Two ratios calculated from an ordinary biochemistry panel perform far better. An alkaline phosphatase to total bilirubin ratio below 4 carried 94% sensitivity and 96% specificity for fulminant Wilson disease in that cohort, and an AST to ALT ratio above 2.2 carried 94% sensitivity and 86% specificity. Used together, the two achieved 100% sensitivity and specificity. The biochemical signature is completed by a Coombs-negative haemolytic anaemia — copper flooding out of dying hepatocytes ruptures red cells — so a young patient with jaundice, anaemia, a strikingly low alkaline phosphatase and a high bilirubin should be discussed with a transplant hepatology unit the same day.

One caveat matters, and it is one most online summaries omit. When those ratios were re-examined in a South Asian paediatric cohort, the alkaline phosphatase to bilirubin ratio detected only about a third of confirmed cases, though it remained highly specific. In other words, these ratios rule in Wilsonian liver failure powerfully but do not rule it out. A normal ratio in a child with acute liver failure and a suggestive picture should never close the question — which is precisely why these patients belong in a centre that can perform the full workup and list for liver transplantation simultaneously.

Treatment: chelation, zinc, and the problem nobody talks about

Two strategies exist, working in opposite directions. Chelating agents — D-penicillamine and trientine — bind copper already deposited in tissues and drive it out through the urine. Zinc salts take the other route, inducing metallothionein in the cells lining the gut so dietary copper is trapped there and never absorbed. Both are supported by current guidance. Choosing between them depends on whether the patient is symptomatic or was picked up presymptomatically, whether the brain is involved, what side effects emerge, and whether the patient is pregnant or planning to be.

Specific dosing belongs in a consultation, and for a clinical reason beyond caution: penicillamine can provoke a paradoxical worsening of neurological symptoms in the early weeks in some patients with neurological disease. Monitoring matters just as much — urinary copper excretion, liver enzymes, blood counts and urine protein need periodic review, because under-treatment lets copper keep accumulating while over-treatment causes its own harm. Dietary restriction of shellfish, organ meats, nuts, chocolate and mushrooms is worth observing, especially in the first year, but diet alone has never treated Wilson disease.

Which brings me to what actually determines outcome. Young patients who feel entirely well stop taking their tablets. I have seen the same story more times than I can count: stable for eight years, treatment quietly abandoned around a marriage or a job change, a return to my clinic in liver failure. Adherence is not a footnote to treatment. Adherence is the treatment. Patients who take their medication faithfully can expect a normal lifespan, and those who have already developed cirrhosis often stabilise rather than progress.

When a transplant is needed — and why the whole family should be tested

Transplantation enters the picture in two circumstances: Wilsonian acute liver failure, where chelation cannot remove copper fast enough to save a failing liver; and decompensated cirrhosis that fails to recover despite adequate medical therapy. The New Wilson Index, developed at King’s College Hospital and published in 2005, combines serum bilirubin, INR, AST and white cell count at presentation; in the original paediatric cohort a score of 11 or above predicted death without transplantation with 93% sensitivity and 98% specificity. It remains widely used, though it was derived in children and in relatively small numbers. Sharpening prognostication here is an active research interest of mine — my group has a manuscript on a dynamic revision of that index under peer review, and I will not quote its findings until it is published.

One point deserves emphasis, because families often misunderstand it. Transplantation corrects the underlying defect rather than merely replacing a damaged organ: ATP7B is made in the liver, so a recipient with a healthy graft handles copper normally and needs no chelation afterwards.

Every new diagnosis is also a finding about a family. Each sibling of an affected patient carries a one-in-four chance of having the disease, and AASLD guidance is clear that first-degree relatives should be screened. A brother identified before any symptoms, treated before copper has scarred his liver, can expect an essentially normal life. Very little else in hepatology delivers that return for a blood test and an eye examination.

If a young relative has unexplained liver enzyme abnormalities, unexplained cirrhosis, or neurological symptoms nobody has accounted for, have Wilson disease formally excluded by a hepatologist rather than assumed away — and never start or stop treatment without your treating doctor. Seeking a second opinion is entirely reasonable. In a condition this treatable, delay is the most expensive mistake available.

Frequently asked questions about Wilson disease

Can Wilson disease be cured?

Not cured in the sense of being eliminated — the genetic defect remains for life — but controlled extremely well. Copper accumulation can be halted and reversed with chelation or zinc therapy, and patients who stay on treatment can expect a normal lifespan. Liver transplantation effectively corrects the metabolic defect, because the new liver produces functioning ATP7B.

Is Wilson disease hereditary? Will my children get it?

Inheritance is autosomal recessive: a child develops the disease only if both parents pass on a faulty copy of the ATP7B gene. Your children will inherit one faulty copy from you, but will develop the disease only if your partner is also a carrier. Genetic counselling and partner testing give a far more precise answer than general statistics.

Can Wilson disease be treated without a liver transplant?

Most patients never need one. Chelating agents or zinc control the disease in the great majority of cases, particularly when diagnosed before significant scarring. Transplantation is reserved for acute liver failure caused by Wilson disease, and for decompensated cirrhosis unresponsive to adequate medical treatment.

How quickly can Wilson disease be diagnosed in an emergency?

Within hours, using tests that are already on a routine blood panel. In acute liver failure, an alkaline phosphatase to total bilirubin ratio below 4 and an AST to ALT ratio above 2.2 together identify fulminant Wilson disease with very high accuracy, and both can be calculated from results a hospital laboratory returns the same day. Ceruloplasmin is far less reliable in this setting and should not delay referral to a transplant centre.

Which foods should be avoided in Wilson disease?

Foods high in copper — shellfish, liver and other organ meats, nuts, chocolate and mushrooms — are best limited, especially during the first year of treatment. Water from copper vessels or copper plumbing is worth checking too. Dietary measures support treatment but never replace it.

Does a normal ceruloplasmin rule out Wilson disease?

No. Ceruloplasmin is an acute-phase reactant, so infection, inflammation, pregnancy and oestrogen-containing medication can lift it into the normal range in someone who genuinely has Wilson disease. In acute liver failure it is particularly unreliable, detecting only a minority of true cases. A borderline result alongside a suggestive clinical picture should prompt 24-hour urinary copper estimation, slit-lamp examination and, where indicated, genetic testing — not closure of the workup.

Author: Dr Chetan Kalal — DM Hepatologist and Liver Transplant Physician, Gleneagles Hospital Mumbai. ORCID: https://orcid.org/0000-0002-5284-7890. This article is general medical education and does not replace individual medical advice.